Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Apr 21, 2025
Date Accepted: Jul 30, 2025

The final, peer-reviewed published version of this preprint can be found here:

Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence–Driven Drug Prescription: Protocol for a Systematic Survey Study

Shen Q, Gong X, Zhang W, Hu Y, Ma Y, Ren Z, Liu S, Song Z, Gale R, Wang J, Chen J

Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence–Driven Drug Prescription: Protocol for a Systematic Survey Study

JMIR Res Protoc 2025;14:e76009

DOI: 10.2196/76009

PMID: 40812739

PMCID: 12395097

Factors affecting the receptiveness of Chinese internists and surgeons towards artificial intelligence-driven drug prescription: Protocol for a systematic survey study

  • Qiujin Shen; 
  • Xiaowen Gong; 
  • Wei Zhang; 
  • Yu Hu; 
  • Yueshen Ma; 
  • Ziyi Ren; 
  • Sichang Liu; 
  • Zhen Song; 
  • Robert Gale; 
  • Jinyu Wang; 
  • Junren Chen

ABSTRACT

Background:

Little is known about the acceptability of using autonomous artificial intelligence (AI) in drug prescription. We hypothesize one major hurdle against testing AI prescription in clinical settings is that we do not understand physicians’ attitudes towards such AI systems.

Objective:

This study aims to collect systematic data on physicians’ attitudes towards AI prescription in China.

Methods:

We designed a questionnaire to interrogate a diverse range of factors that may affect physicians’ receptiveness to an AI prescription system, including the physician’s personal attributes and perceived importance of various technological, institutional, and governmental attributes. We will focus on hospitals and physicians with higher patient volumes, and the survey will be conducted in two phases. In Phase 1, survey will be limited to the Tianjin metropolitan area, enlisting >250 physicians from approximately 2 tier-1, 3 tier-2, and 3 tier-3 hospitals to respond to the questionnaire. In the subsequent Phase 2 we will survey metropolitan areas in ≥10 additional province-level administrative divisions, with balanced representation of the Pacific coast and the less-developed inland regions and collecting returned questionnaires from >1250 physicians from >15 tier-1, >15 tier-2, and >15 tier-3 hospitals. Clustering, geo-spatial, and multi-variable analyses will be conducted on the response data to identify distinct physician ‘profile-types’, map the composition and variance of physician profile-types across diverse metropolitan areas, and delineate how a physician’s profile-type might affect his/her receptiveness to AI prescription.

Results:

Survey results and their analyses will be published in a peer-review journal.

Conclusions:

We believe data and analytical insights generated from this study will assist policy makers and AI researchers in making informed decisions on whether AI prescription is a valuable research direction and which use cases of AI prescription are more acceptable to physicians.


 Citation

Please cite as:

Shen Q, Gong X, Zhang W, Hu Y, Ma Y, Ren Z, Liu S, Song Z, Gale R, Wang J, Chen J

Factors Affecting the Receptiveness of Chinese Internists and Surgeons Toward Artificial Intelligence–Driven Drug Prescription: Protocol for a Systematic Survey Study

JMIR Res Protoc 2025;14:e76009

DOI: 10.2196/76009

PMID: 40812739

PMCID: 12395097

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.